Corporate Update: Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc. (AGIO) advanced 1.47 % during the 24‑hour session that concluded at 07:35 PM Central Europe on Thursday, 22 October 2026. At the close, one share traded for approximately USD 36.77 on major exchanges, reflecting a modest but steady upward trajectory in the company’s valuation.
Trading Metrics
| Item | Value |
|---|---|
| Shares Outstanding | 59.8 million |
| Market Capitalisation | USD 2.2 billion |
| 24‑Hour Volume | USD 31.6 million |
| Year‑to‑Date Gain (since last month‑end) | +6.32 % |
| 200‑Day Simple Moving Average | USD 31.41 |
| 52‑Week High | USD 46 (18 November 2025) |
| 52‑Week Low | USD 22.24 (19 November 2025) |
These figures underscore a firm that has maintained a solid liquidity profile while demonstrating resilience amid broader market volatility.
Recent SEC Filing
On 21 October 2026, Agios filed a Rule 144 notice with the U.S. Securities and Exchange Commission, announcing a proposed sale of its common shares. The filing details that Sarah Gheuens, an officer of Agios, intends to sell approximately 1,489 shares as part of a stock‑option exercise transaction. The sale will be executed through Morgan Stanley Smith Barney and will be listed on the NASDAQ. The notice references an earlier transaction earlier that year, in which 30,000 shares were sold, generating six‑figure proceeds. No additional securities have been reported as sold in the preceding three months. Agios reaffirms that its principal address remains at 88 Sidney Street, Cambridge, Massachusetts.
Contextualising Agios within the Broader Market
The 24‑hour trading window also saw mixed performance among comparable stocks:
- Astronics Corp. (ATRO) rose 3.29 % to USD 58.58, despite a modest decline in its share price during the session. The company’s market cap stands at USD 2.6 billion with a P/E of 34.3.
- Customers Bancorp Inc. (CUBI) increased 0.38 % to USD 79.22. Its market cap is USD 2.6 billion, and it trades at a P/E of 9.25. The firm is slated to present its Q3 2026 earnings on 22 October 2026.
- Power Integrations Inc. (POWI) climbed 2.73 % to USD 47.54. It maintains a market cap of USD 2.6 billion and a high P/E of 107.29, reflecting a recent uptick in investor confidence.
- Transmedics Corp. (TMDX) fell 3.14 % to USD 71.32, holding a market cap of USD 2.6 billion with a P/E of 18.47.
- Mbx Biosciences Inc. (MBX) edged up 0.8 % to USD 51.59, also at a market cap of USD 2.6 billion.
These movements illustrate the sector’s volatility while highlighting Agios’s relative steadiness.
Company Profile
Agios Pharmaceuticals Inc. is a biotechnology firm headquartered in Cambridge, Massachusetts, operating within the health‑care sector with a specialization in cancer metabolism. The company’s research focuses on developing therapeutics that target key metabolic pathways—including glycolysis, fatty‑acid metabolism, and autophagy—critical to cancer cell growth and survival. By concentrating on these pathways, Agios seeks to deliver novel treatments that could improve outcomes for patients with hard‑to‑treat malignancies.
This article is intended to provide a concise, data‑driven overview of Agios Pharmaceuticals’ recent trading activity, SEC filing, and market context. The narrative style aims to make complex financial details accessible to a broad audience.
